What were Jagsonpal Pharmaceuticals Ltd's latest quarterly results?
Jagsonpal Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -65.6%
- Revenue Growth YoY: -1.4%
- Operating Margin: 22.0%
Jagsonpal Pharmaceuticals Ltd: Stock Analysis & Fundamentals
Updated this weekJagsonpal Pharmaceuticals Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 29.0. ROE: 18.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
What's Happening
🏦Virtually debt-free company
Key Numbers
Current Price
₹185
Dividend Yield
1.35%
Market Cap
1.2K Cr
Valuation
N/AOther Top Pharma - API Stocks Beating Nifty 500
Frequently Asked Questions: Jagsonpal Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Jagsonpal Pharmaceuticals Ltd's current PE ratio?
Jagsonpal Pharmaceuticals Ltd's current PE ratio is 29.0x.
- Current PE: 29.0x
- Market Cap: 1.2K Cr
- Dividend Yield: 1.35%
What is Jagsonpal Pharmaceuticals Ltd's price-to-book ratio?
Jagsonpal Pharmaceuticals Ltd's price-to-book ratio is 4.9x.
- Price-to-Book (P/B): 4.9x
- Book Value per Share: ₹38
- Current Price: ₹185
Is Jagsonpal Pharmaceuticals Ltd a fundamentally strong company?
Jagsonpal Pharmaceuticals Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 23.0%
Is Jagsonpal Pharmaceuticals Ltd debt free?
Jagsonpal Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹9 Cr
What is Jagsonpal Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Jagsonpal Pharmaceuticals Ltd's return ratios over recent years
- FY2023: ROCE 25.0%
- FY2024: ROCE 17.0%
- FY2025: ROCE 23.0%
Is Jagsonpal Pharmaceuticals Ltd's cash flow positive?
Jagsonpal Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹55 Cr
- Free Cash Flow (FCF): ₹10 Cr
- CFO/PAT Ratio: 100% (strong cash conversion)
What is Jagsonpal Pharmaceuticals Ltd's dividend yield?
Jagsonpal Pharmaceuticals Ltd's current dividend yield is 1.35%.
- Dividend Yield: 1.35%
- Current Price: ₹185
Who holds Jagsonpal Pharmaceuticals Ltd shares — promoters, FII, DII?
Jagsonpal Pharmaceuticals Ltd's shareholding pattern (Dec 2025)
- Promoters: 67.4%
- FII (Foreign): 2.1%
- DII (Domestic): 0.1%
- Public: 30.3%
Is promoter holding increasing or decreasing in Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 67.4% (Dec 2025)
- Previous Quarter: 67.5% (Sep 2025)
- Change: -0.15% (decreasing — worth monitoring)
Is Jagsonpal Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Jagsonpal Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Jagsonpal Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Jagsonpal Pharmaceuticals Ltd may be worth studying
- Cash flow is positive — CFO ₹55 Cr
What is the investment thesis for Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd investment thesis summary:
What is the future outlook for Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.